Skip to main content

MoonLake Immunotherapeutics

MLTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001821586

In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 6 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.

13F holders, Q4 2022

Institutional positions in MoonLake Immunotherapeutics as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
33
+10 vs. Q3 2022
Shares held
37.7M
+960.7K (+2.6%) vs. Q3 2022
Total value
$396.4M
+$105.5M (+36.3%) vs. Q3 2022
New holders
14
6 more added
Sold out
4
7 more reduced

1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting MLTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2022: 33 institutions
Q1 2021: 42 institutionsQ2 2021: 46 institutionsQ3 2021: 43 institutionsQ4 2021: 45 institutionsQ1 2022: 27 institutionsQ2 2022: 23 institutionsQ3 2022: 24 institutionsQ4 2022: 33 institutionsQ1 2023: 43 institutionsQ2 2023: 83 institutionsQ3 2023: 118 institutionsQ4 2023: 125 institutionsQ1 2024: 114 institutionsQ2 2024: 111 institutionsQ3 2024: 109 institutionsQ4 2024: 116 institutionsQ1 2025: 136 institutionsQ2 2025: 130 institutionsQ3 2025: 134 institutionsQ4 2025: 130 institutionsQ1 2026: 147 institutionsQ2 2026: 172 institutions
Value heldQ4 2022: $396.4M
Q1 2021: $108.9MQ2 2021: $115.8MQ3 2021: $111.1MQ4 2021: $112.8MQ1 2022: $123.4MQ2 2022: $190.1MQ3 2022: $291.4MQ4 2022: $396.4MQ1 2023: $843.2MQ2 2023: $2.86BQ3 2023: $3.21BQ4 2023: $3.53BQ1 2024: $2.99BQ2 2024: $2.67BQ3 2024: $3.14BQ4 2024: $3.43BQ1 2025: $2.34BQ2 2025: $2.77BQ3 2025: $269.7MQ4 2025: $742.9MQ1 2026: $1.17BQ2 2026: $1.43B
Institutions holding MLTX and their total value by quarter
QuarterHoldersValue
Q2 2026172$1.43B
Q1 2026147$1.17B
Q4 2025130$742.9M
Q3 2025134$269.7M
Q2 2025130$2.77B
Q1 2025136$2.34B
Q4 2024116$3.43B
Q3 2024109$3.14B
Q2 2024111$2.67B
Q1 2024114$2.99B
Q4 2023125$3.53B
Q3 2023118$3.21B
Q2 202383$2.86B
Q1 202343$843.2M
Q4 202233$396.4M
Q3 202224$291.4M
Q2 202223$190.1M
Q1 202227$123.4M
Q4 202145$112.8M
Q3 202143$111.1M
Q2 202146$115.8M
Q1 202142$108.9M

Institutions, Q4 2022

Shares, value and share of portfolio for each institution holding MoonLake Immunotherapeutics; share changes are against Q3 2022.

Institutions holding MLTX in Q4 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Royal Bank of Canada76$1.00K0.00%+76New
Bank of America Corp7,900$83.0K0.00%+7,900New
Goldman Sachs Group Inc10,110$106.2K0.00%−100−1.0%Reduced
Geode Capital Management, LLC11,451$120.0K0.00%+11,451New
Renaissance Technologies LLC11,609$122.0K0.00%+11,609New
Two Sigma Investments, LP12,385$130.0K0.00%+12,385New
Virtu Financial LLC14,395$151.0K0.02%+14,395New
Meridian Wealth Management, LLC15,000$154.3K0.02%−12,000−44.4%Reduced
SVB Financial Group16,173$169.8K0.46%+16,173New
Morgan Stanley27,365$287.3K0.00%+24,265+782.7%Added
Cheyne Capital Management (UK) LLP32,129$337.4K0.60%+32,129New
JPMorgan Chase & Co44,844$471.0K0.00%+44,844New
Barclays PLC55,952$587.5K0.00%+40,768+268.5%Added
TD Asset Management Inc67,312$706.8K0.00%00.0%Unchanged
Jefferies Financial Group Inc.67,654$710.4K0.01%+67,654New
UBS Group AG73,388$770.6K0.00%−2,276−3.0%Reduced
Acuta Capital Partners, LLC93,500$981.8K0.60%+93,500New
Citigroup Inc166,317$1.75M0.00%+7,230+4.5%Added
FMR LLC185,500$1.95M0.00%−633,677−77.4%Reduced
Balyasny Asset Management LLC217,999$2.29M0.01%+118,125+118.3%Added
Tang Capital Management LLC245,714$2.58M0.37%−13,340−5.1%Reduced
Tekla Capital Management LLC300,000$3.15M0.12%00.0%Unchanged
Braidwell LP381,120$4.00M0.13%+381,120New
AXA S.A.405,284$4.26M0.02%+405,284New
RTW Investments, LP500,000$5.25M0.11%00.0%Unchanged
Great Point Partners LLC642,566$6.75M1.39%+150,566+30.6%Added
BlackRock Inc.741,758$7.79M0.00%−740.0%Reduced
Price T Rowe Associates Inc822,601$8.64M0.00%−46,787−5.4%Reduced
Polar Capital Holdings Plc876,377$9.20M0.07%+876,377New
TCG Crossover Management, LLC1,000,000$10.5M1.85%00.0%Unchanged
Citadel Advisors LLC2,886,092$30.3M0.04%+200,155+7.5%Added
Cormorant Asset Management, LP6,065,001$63.7M4.28%00.0%Unchanged
BVF Inc21,751,284$228.4M9.64%00.0%Unchanged
Point72 Asset Management, L.P.0$00.00%−335,000−100.0%Sold out
Ghost Tree Capital, LLC0$00.00%−300,000−100.0%Sold out
Monashee Investment Management LLC0$00.00%−191,945−100.0%Sold out
Alps Advisors Inc0$00.00%−20,144−100.0%Sold out
Jefferies Group LLC––––Not filed